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Enhancement of Th1/Th17 
inflammation by TRIM21 in 
Behçet’s disease
Yuri Ahn1, Ji-Hye Hwang1, Zhenlong Zheng1,2, Dongsik Bang3 & Do-Young Kim  1
The etiology of Behçet’s disease (BD), a chronic, multisystemic autoinflammatory and autoimmune 
disease, remains unknown; however, researchers have postulated that infectious agents, such as 
herpes simplex virus, are significant triggering factors of BD. Tripartite motif-containing (TRIM) proteins 
exhibit antiviral properties, mediating antiviral defense mechanisms. The purpose of this study was 
to investigate TRIM21 protein expression in the monocytes of BD patients and to identify the role of 
TRIM21 in immune dysregulation in BD. In this study, the expression of TRIM21 and related molecules, 
including interferon regulatory factor 8 (IRF8), was analyzed in monocytes from BD patients. Functional 
analyses using small interfering RNA and co-culture with responder T cells were performed to examine 
the pathological role of TRIM21 in BD. Peripheral blood monocytes from BD patients showed increased 
TRIM21 expression and decreased IRF8 expression compared with that in monocytes from healthy 
controls. TRIM21 was found to decrease IRF8 expression. BD monocytes facilitated Th1 and Th17 
differentiation of co-cultured T cells, and knock-down of TRIM21 expression by small interfering RNA 
inhibited this differentiation. In conclusion, TRIM21 played a pivotal role in regulating the secretion of 
proinflammatory cytokines in monocytes of BD patients.
The tripartite motif-containing (TRIM) family of proteins has been recognized for its role in regulating the innate 
immune response to viral infections. TRIM proteins are structurally characterized by a Really Interesting New 
Gene (RING) domain, a B-box domain, and a coiled-coil domain. TRIM21 is an E3 ubiquitin ligase that regulates 
innate immune responses by ubiquitinating various intracellular proteins, such as nuclear factor kappa B (NF-kB) 
and interferon (IFN) regulatory factors (IRFs). NF-κB is widely involved in the expression of proinflammatory 
genes, including cytokines, chemokines, and adhesion molecules, and TRIM21 promotes NF-kB signaling, espe-
cially during infectious conditions1. Multiple IRFs are tightly regulated by TRIM21 in immune cells2. For exam-
ple, TRIM21 interacts and ubiquitinates IRF3, IRF7, and IRF83, 4. IRFs play a critical role in inhibiting Th17-cell 
differentiation, acting as intrinsic transcriptional inhibitors5.
Behçet’s disease (BD) is a chronic, multisystemic, inflammatory condition characterized by mucocutaneous 
lesions and vasculitis on various organs6. Although the exact etiology remains unknown, dysregulated innate 
and acquired immune systems have been implicated in the pathogenesis7. Recent studies have shown that Th1 
and Th17 T cells play the pivotal pathogenic role in BD8–10. However, the mechanism of these pathologic T-cell 
responses remains elusive. Because human monocytes trigger and polarize Th responses and regulate T-cell 
responses during infection and in autoimmune diseases, monocytes and their progeny, such as macrophages, 
appear to play an important role in BD pathogenesis11–13.
Based on the hypothesized role of monocytes in BD and previous observations of TRIM21 in other immune 
related disorders, we decided to investigate the functional role of monocyte TRIM21 in the abnormal T-cell 
response in BD. Thus, we sought to elucidate TRIM21 protein expression in monocytes of BD patient and to 
identify the role of TRIM21 on Th1/Th17 immune deviation in BD.
Materials and Methods
Ethics Statement. Each participant provided written informed consent before enrollment in this study, and 
the protocols was approved by the Institutional Review Board of Severance Hospital, Yonsei University College 
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of Medicine, Seoul, Korea (IRB number: 4-2016-0391) in accordance with the ethical guidelines of the Helsinki 
Declaration. All samplings and experiments followed the approved guidelines.
Patients. Korean BD patients who visited the BD Specialty Clinic of Severance Hospital and fulfilled the diag-
nostic criteria of the International Study Group for BD and healthy control volunteers were recruited14. Patients 
with other concomitant autoimmune diseases, malignancies, or infections were excluded from the study. The clin-
ical features of BD were identified by trained dermatologists based on medical history and physical examination. 
Venous blood samples were collected from all participants.
Isolation of monocytes and T cells from peripheral blood. Peripheral blood mononuclear 
cells (PBMCs) were separated from heparinized venous blood using Ficoll-Hypaque (GE Healthcare, 
Buckinghamshire, UK) density-gradient centrifugation. Highly purified T cells and monocytes were prepared 
from PBMCs by exhaustive immunomagnetic negative selection in an MACS separator (Miltenyi Biotec, Bergish 
Gladbach, Germany) using a T Cell Negative Isolation Kit and a Pan Monocyte Negative Isolation Kit (Miltenyi 
Biotec, Bergish Gladbach, Germany).
Small interfering RNA(siRNA) transfection. Four different TRIM21-targeting siRNAs was purchased 
from Qiagen (Germany). Primary monocytes and THP-1 cells were transfected with 10 nM of siRNA using lipo-
fectamine 2000 (Invitrogen, USA) according to the manufacturer’s protocols. Knock-down efficiencies were ana-
lyzed 24 h after transfection by western blot analysis.
Confocal microscopy. Primary monocytes were grown for 24 h on Lab-Tek eight-well Permanox chamber 
slides (Thermo Fisher Scientific, San Jose, USA). Cells were fixed with 4% paraformaldehyde for 10 min and per-
meabilized with 0.1% Triton X-100. After blocking with 1% bovine serum albumin in phosphate-buffered saline 
for 30 min, they were then incubated with anti-TRIM21 Alexa 488 (Bioss, Woburn, USA) for 1 h at 37 °C in the 
dark. The cells were washed, and mounting media with 4′,6-diamidino-2-phenylindole (DAPI) was added to the 
slide. The slide was analyzed with a ZEISS immunoconfocal microscope.
Western blot. Freshly isolated monocytes and stimulated monocytes were lysed in radioimmunoprecipita-
tion assay buffer containing protease inhibitors and phosphatase inhibitor (GeneDipot, Barker, USA). Protein was 
quantified using bicinchoninic acid assay. Cell lysates were resolved by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and analyzed by western blot using specific antibodies against TRIM21 (Proteintech, USA), IRF8 
(Cell signaling, UK), and phosphor-p65 (Cell signaling). Western blot band signal densities for TRIM21, IRF8, 
and phosphor-p65 were normalized to those of a loading control (glyceraldehyde 3-phosphate dehydrogenase 
[GAPDH]) and averaged from three independent experiments.
Real-time polymerase chain reaction (RT-PCR). For RNA isolation, cells were harvested and total 
RNA isolated using Trizol reagent (Invitrogen) according to the manufacturer’s protocol. cDNA was synthe-
sized with an oligo (dT) primer and the Superscript II reverse transcriptase system followed by RT-PCR using 
SYBR Green Master Mix (Applied Biosystems, Foster City, USA). Primer sequences were as follows: inter-
leukin(IL)-17A, forward ACCAATCCCAAAAGGTCCTC and reverse GGGGACAGAGTTCATGTGGT; 
IFN-γ, forward TGACCAGAGCATCCAAAAGA and reverse CTCTTCGACCTCGAAACAGC; IL-4, 
forward GCCACCATGAGAAGGACACT and reverse ACTCTGGTTGGCTTCCTTCA; IL-13, forward 
GTACTGTGCAGCCCTGGAAT and reverse TTTACAAACTGGGCCACCTC.
NF-kB luciferase assay. THP-1 cells were seeded at a density of 65,000 cells per well in 12-well plates 1 day 
prior to transfection. Cells were transfected with NF-kB-Luc reporter plasmid (500 ng/ml) and β-galactosidase 
(β-gal, 500 ng/ml) for 24 h. Cells were harvested and luciferase assay performed using the Luciferase Assay Kit 
(Promega, USA) according to the manufacturer’s protocol. Cells were lysed in 150 μl 1 × lysis buffer and centri-
fuged at 12,000 g for 15 s, and luminescence in the supernatant was measured using the luciferase assay reagent. 
Values were normalized by results of a β-gal assay using the β-galactosidase Kit (Promega). For this assay, 50 μl 
of the lysate supernatant was incubated with 50 μl 2 × assay buffer at 37 °C for 30 min, and the resulting yellow 
color was quantified by absorbance at 420 nm. β-gal activity in each of the lysates was obtained using a standard 
curve, and NF-kB-luciferase activity was normalized against β-gal activity, averaged for three independent sets 
of experiments, and plotted.
Co-culture conditions. Monocytes (4 × 105/ml) and T cells (4 × 105/ml) were seeded in 12-well plastic tis-
sue culture plates (Corning, Cambridge, USA). Co-cultures were maintained for 7 days in complete Roswell Park 
Memorial Institute medium 1640 (Hyclone) containing 10% fetal bovine serum, L-glutamine (2 mM), penicillin 
(100 units/ml), and streptomycin (100 μg/ml) in the presence of 1 μg/ml soluble anti-CD3 antibody (eBioscience, 
USA) and 100 ng/ml lipopolysaccharide (LPS, Sigma, USA). After 7 days of culture, cells were stimulated with 
50 ng/ml phorbol myristate acetate (PMA; Sigma) and 1 μg/ml ionomycin (Sigma) for 6 h, with Golgistop (BD 
Biosciences, USA) present for the last 4 h. For intracellular staining, we used a human Th1/Th17 phenotype kit for 
flow cytometry according to the manufacturer’s protocol (BD Biosciences).
Flow cytometry. For intracellular staining, monocytes from healthy and BD patients were incubated with 
anti-human TRIM21 for 30 min at RT and added to FITC-conjugated anti-IgG secondary antibody for 15 min 
at RT. HeLa cells, which have elevated TRIM21 levels, also used as positive control. For co-cultured CD4+ 
cells, we used a human Th1/Th17 phenotype kit for flow cytometry according to the manufacturer’s protocol 
(BD Biosciences). Cells were stained for 30 min at RT with the following antibody cocktail: FITC-conjugated 
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anti-human IFN-γ, PE-conjugated anti-human IL-17A, and PerCP-Cy5.5-conjugated anti-human CD4. After 
washing, cells were fixed in 4% paraformaldehyde and analyzed using an LSRII cytometer (BD Biosciences) and 
Flowjo software.
Enzyme-linked immunosorbent assay (ELISA). Supernatants from the co-cultures were collected, 
centrifuged to remove cell debris, and stored at −70 °C for future cytokine measurements. The IL-17 levels 
(eBioscience) were determined using an ELISA kit according to the manufacturer’s instructions. Supernatants 
from healthy and BD monocytes after LPS stimulation were analyzed with IL-6, IL-1β, IL-23 (eBioscience), and 
IL-12/23p40 (R&D Systems, USA) ELISA kits according to the manufacturers’ instructions.
Statistical analyses. Statistical analyses were conducted using Graph Pad Prism, version 4.03 (GraphPad 
Software, Inc., San Diego, CA). Data are expressed as the mean ± standard deviation (SD) for parametric data 
and as the median and interquartile range for nonparametric data. The significance of differences between two 
groups was determined using a two-tailed Student’s t-test or Wilcoxon signed-rank test. For multiple compari-
sons, one-way analysis of variance with a Bonferroni test was used. A P-value < 0.05 was considered statistically 
significant.
Results
Increased TRIM21 expression in BD monocytes. To confirm the clinical significance of TRIM21 in BD, 
we first examined the expression of TRIM21 in freshly isolated monocytes from BD patients and healthy controls. 
Western blot analysis showed that TRIM21 expression in monocytes was significantly higher in BD patients 
(n = 18) than in healthy controls (n = 5) (P = 0.0009, Fig. 1a and b). Confocal immunofluorescence microscopy 
using an anti-TRIM21 antibody also revealed greater TRIM21 expression in both the cytosol and nucleus of 
Figure 1. Monocytes from Behçet’s disease patients exhibited increased TRIM21 expression compared to those 
from healthy controls. (a and b) Human monocytes isolated from healthy volunteers and BD patients. TRIM21 
protein levels in monocytes from 18 BD patients and five healthy control subjects, as determined by western 
blot (a). TRIM21 expression was quantified by densitometry following normalization to GAPDH expression 
as indicated in accompanying graph (b). Data are expressed as the mean ± SD. **P < 0.01. The cropped blots 
are displayed and full-length blots are shown in the Supplementary Information. (c) Endogenous TRIM21 was 
visualized by immunofluorescence using anti-TRIM21 (green) and DAPI (blue) and observed under confocal 
microscopy. Scale bar represents 20 μm.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 3018  | DOI:10.1038/s41598-017-03251-5
monocytes from BD patients compared with healthy controls (Fig. 1c). TRIM21 expression in BD monocytes 
was also validated using flow cytometric analysis (Supplementary Figure 1A). HeLa cells, which have elevated 
TRIM21 levels, were used as positive control15. From these observations, we confirmed that TRIM21 expression 
was significantly higher in monocytes from BD patients.
IRF8, a representative downstream target of TRIM21, was decreased in BD mono-
cytes. TRIM21 interacts with IRF8 upon toll-like receptor(TLR)/IFN-γ stimulation, resulting in 
TRIM21-mediated ubiquitination of IRF816, 17. IRF8 expression was lower in BD monocytes than in those from 
healthy controls (Fig. 2a and b). To investigate the direct regulation of IRF8 by TRIM21, TRIM21 was knocked 
down using siRNA. TRIM21 was silenced using commercially available siRNA duplexes against TRIM21, which 
resulted in >60% knock-down of TRIM21 in both THP-1 and isolated human monocytes from healthy donors 
(Supplementary Figure 2A). IRF8 levels increased with TRIM21 knock-down in primary monocytes from 
healthy controls and THP-1 cells from an established human monocyte cell line (Fig. 2c and d). IRF8 is ubiquit-
inated by TRIM21, which promotes secretion of IL-12/23p40 after TLR/IFN-γ stimulation16. To assess whether 
IL-12/23p40 secretion was affected by the increased TRIM21, we measured IL-12/23p40 secretion by monocytes 
from both BD patients and healthy controls after TLR4 stimulation by LPS. BD monocytes exhibited increased 
secretion of IL-12/23p40 in response to LPS than did healthy monocytes (Fig. 2e). However, BD monocytes with 
silenced TRIM21 secreted significantly smaller amounts of IL-12/23p40 in response to LPS stimulation (Fig. 2f). 
From these results, we concluded that TRIM21 down-regulated IRF8 and enhanced the secretion of IL-12/23p40 
in BD monocytes.
BD monocytes induced secretion of Th17 promoting cytokines via TRIM21-dependent path-
way. TRIM21 upregulates proinflammatory cytokines through recognized antibody-bound antigen and 
TLR response. To confirm whether TRIM21 promoted inflammatory cytokine secretion after TLR stimulation, 
secretion of IL-6, IL-1β, and IL-23 were measured in freshly isolated human monocytes after LPS stimulation. 
BD monocytes exhibited increased IL-6, IL-1β, and IL-23 secretion compared with healthy control monocytes 
(Fig. 3a). To identify the role of increased TRIM21 on cytokine secretion in monocytes, we knocked down 
TRIM21 in freshly separated primary monocytes using siRNA. Knock-down of TRIM21 in monocytes signif-
icantly decreased IL-6 and IL-1β cytokine secretion, and IL-23 secretion was also slightly decreased, but not 
significantly so (Fig. 3b). IL-6, IL-1β and IL-23 are thought to play significant roles in differentiating naïve T 
cells into pathogenic Th17 cells; our results suggest that increased TRIM21 in monocytes triggered the release of 
Th17-promoting cytokines under TLR4 stimulation by LPS.
BD monocytes show increased NF-kB activation after TLR stimulation. TRIM21 promotes NF-kB 
signaling in response to TLR agonists, such as viral and bacterial antigens1. We hypothesized that up-regulated 
TRIM21 might have increased secretion of Th17-promoting cytokines by modulating upstream NF-kB activa-
tion. To determine whether the increased TRIM21 enhanced NF-kB activation, monocytes from BD patients and 
healthy controls were stimulated with 1 µg/ml LPS for 1 h and p-p65 was identified by western blot analysis. BD 
monocytes exhibited increased p-p65 levels compared with healthy monocytes (Fig. 4a and b), and knock-down 
of TRIM21 in THP-1 cells using siRNA decreased the level of p-p65 (Fig. 4c and d). To confirm whether TRIM21 
regulated the NF-kB pathway, we performed promoter analyses using an NF-kB activity reporter assay in cells 
stimulated with LPS. Knock-down of TRIM21 in THP-1 cells stimulated with LPS significantly decreased NF-kB 
reporter activity (Fig. 4e). These results suggest that the enhanced secretion of inflammatory cytokines from BD 
monocytes may have been mediated by increased NF-kB activation.
BD monocytes promoted Th17 differentiation in T-cell co-culture. To investigate the patho-
physiologic significance of cytokines produced by BD monocytes, we performed co-cultures with BD mono-
cytes and responder CD4 T cells as previously described18. After 7-day co-culture using monocytes (4 × 105/
ml) and allogeneic responder CD4+ T cells (4 × 105/ml) from healthy controls, the proportion of IL-17+ and 
IL-17+/IFN-γ+ producing T cells was increased in BD monocyte-responder T cell cultures compared with that 
in control monocyte-responder T cell co-cultures (Fig. 5a and b). The increased soluble IL-17A production 
in BD monocyte- responder T cell co-culture supernatant was confirmed using ELISA (Fig. 5c). Interestingly, 
responder CD4 + T-cell culture with TRIM21-silenced BD monocytes significantly lowered mRNA expression 
of both IL17A and IFNG, but not IL4 or IL13, using Th2 cytokines as control (Fig. 5d). Collectively, these results 
support the conclusion that the Th1- and Th17-priming role of BD monocytes was partly dependent on increased 
TRIM21.
Discussion
We have uncovered a novel regulatory function of TRIM21, one that plays a critical role in inflammatory cytokine 
production in activated monocytes from BD patients. TRIM21 regulated important target pathways, such as IRF8 
and NF-kB, and modulated proinflammatory cytokine production in monocytes.
The evidence supports a new pathogenic model in which the modulation of ubiquitination is responsible 
for the distinct immune reaction in BD19. TRIM proteins activate innate immune signaling pathways, including 
NF-kB, AP-1, and IRFs, by generating ubiquitin signals20. A recent genetic study on BD revealed that TRIM39 
is associated with a genetic predisposition to this disease21. TRIM39 regulates the NF-κB signal negatively by 
modulating the production of inflammatory cytokines, such as TNF-α19. From the classical view on the immuno-
logic abnormalities in BD patients, strong Th1 immune response occurs in active BD22. BD patients exhibit high 
levels of TNF-α, IFN-γ and IL-1 in peripheral circulation10, 23. This recent research on TRIM39 revealed TRIM 
protein modulation of ubiquitination as important in skewed immune polarization in BD. In the future, we hope 
to discover the role of TRIM21 protein in the fine-tuning of immune polarization, especially in Th17 response.
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TRIM21 interacts with numerous proteins involved in both innate and adaptive immunity24. The primary role 
of TRIM21 is to sense intracellular antibodies during viral infection, but TRIM21 also activates innate immune 
signaling pathways, including NF-kB and IRFs20. Recent linkage analysis found IRB8, an ubiquitinating target 
of TRIM21, is altered in BD; and dysregulation of IRF8 is associated with altered cytokine expression, espe-
cially Th17 response in BD25, 26. IRF8 regulates the expression of inflammatory cytokines, such as IL-12/23p40, 
in macrophages and, presumably, their precursors, monocytes16. Active BD exhibits increased Th17 response 
characterized by increased IL-17, which prompts us to consider the pathogenic role of this proinflammatory 
pattern in the pathogenesis of BD9, 10, 25. Consistent with our results from the co-cultures between monocyte and 
Figure 2. The expression of IRF8, a representative target of TRIM21 ubiquitination, was also decreased in BD 
monocytes. (a) IRF8 protein levels in monocytes from 18 BD patients and five healthy control subjects, as determined 
by western blot. Cell lysates were from the same sample used in the analysis depicted in Fig. 1a and b. Primary 
monocytes (c) and THP-1 cells (d) were transfected with scrambled RNA or TRIM21 siRNA (10 nM) for 24 h. 
Expression of TRIM21 and IRF8 was detected by immunoblotting. TRIM21 and IRF8 expression was quantitated 
by densitometry following normalization to GAPDH expression as indicated in the accompanying graph. Data are 
represented as the mean ± SD. (e) Monocytes isolated from healthy controls or BD patients were stimulated with LPS 
(1 µg/ml) for 24 h. Supernatants were collected, and secretion of IL-12/23p40 was measured by ELISA. (f) Primary 
monocytes from healthy controls were transfected with scrambled RNA or TRIM21 siRNA (10 nM) for 24 h, and 
the transfected cells were stimulated with LPS (1 µg/ml) for 24 h, and the secretion of IL-12/23p40 was measured by 
ELISA. Data are represented as the mean ± SD. *P < 0.05. **P < 0.01. ***P < 0.001. The cropped blots are displayed 
and full-length blots are shown in the Supplementary Information.
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responder T cells, researchers have observed excessive CD4+ T cells producing IL-17 and IFN-γ (Th1/Th17) cells 
in BD patients27.
Th17 cells are characterized by type 17 signature cytokines, such as IL-17, IL-22, IFN-γ, and GM-CSF. The 
development and expansion of Th17 cells is dependent on specific cytokine combinations, such as IL-1β, IL-6, 
and TGF-β; and IL-23 stabilizes and potentiates the pathogenic ability of Th1728. The main cellular sources of 
these Th17-promoting cytokines varies depending on the cytokines, but monocytes are also an important source 
of IL-1β or IL-629. We demonstrated that repressed TRIM21 expression in monocytes inhibited Th17 and Th1 
immune deviation, not Th2 response, using siRNA and the co-culture method. TRIM21 regulated the production 
of IL-1β and IL-6 from LPS-activated monocytes. Although IL-23 induces Th17 response during T-cell develop-
ment, IL-23 is not indispensable in priming the Th17 cells28.
TRIM21 directly regulates important signaling-modulated inflammation, including IRF and NF-kB pathway, 
as mentioned earlier20. The regulation of IRF8 by TRIM21 is suggested directly via ubiquitination in the nucleus 
of macrophages16. Again, from our data, when we suppressed the expression of TRIM21 in both primary mono-
cytes and THP-1 cells, IRF8 was significantly down-regulated. IRF8 regulates the differentiation and functions of 
monocytes30. Moreover, IRF8 regulates macrophage maturation, survival, and innate immune responses, includ-
ing autophagy31. In addition, IRF8 induces a cytokine milieu that favors Th1 and Th17 response by enhancing 
TGF-β production from antigen-presenting cells32. However, the regulation of the NF-kB pathway by TRIM21 
appears to be more complicated. Although TRIM21 is not required for constitutive NF-κB signaling, TRIM21 
activates NF-κB signaling after intracellular sensing of pathogen1. The stimulation of TRIM21 on NF-κB activa-
tion is dependent on various signaling, such as Transforming growth factor beta-activated kinase 1 (TAK1), IκB 
kinase-α (IKKα), and IκB1. Interestingly, TRIM21-/- mice showed increased dysregulation of NF-kB-mediated 
proinflammatory cytokine production33, 34. Because TRIM21 regulates various signaling pathways on different 
cell types in vivo, overall biological consequences may demonstrate conflicting results from various cellular levels.
The main limitation of our study is that we did not clearly define the role of monocyte in co-culture with 
responder T cells. Monocytes play key roles during inflammation and pathogen challenge. Different subsets of 
monocytes exhibit different functions, including coordination of inflammation by recruiting inflammatory cells 
and generating monocyte-derived dendritic cells or macrophages35. Different monocyte subsets have been iden-
tified by differential expression of CD14 and CD1636, 37. Classical monocytes, which are strongly positive for 
CD14, constitute the majority of monocytes in healthy individuals; and monocytes expressing CD16 account 
for less than 15% of all monocytes during homeostasis but increase significantly during infectious diseases and 
Figure 3. BD monocytes showed increased secretion of Th17-promoting cytokines, and knock-down of 
TRIM21 decreased cytokine secretion. (a) Monocytes isolated from healthy controls or BD patients were 
stimulated with LPS (1 µg/ml) for 24 h. Supernatants were collected, and secretion of IL-1β, IL-6, and IL-23 
was measured by ELISA. (b) Primary monocytes from healthy controls were transfected with scrambled 
RNA or TRIM21 siRNA (10 nM) for 24 h, and the transfected cells were stimulated with LPS (1 µg/ml) for 
24 h. Supernatants were collected; and secretion of IL-1β, IL-6, and IL-23 was measured by ELISA. Data are 
represented as the mean ± SD. *P < 0.05, **P < 0.01 compared with LPS stimulation or TRIM21 knock-down 
in monocytes in healthy monocytes.
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inflammatory disorders38, 39. BD patients also demonstrated increased CD16+ monocytes in peripheral blood 
(our observation, unpublished). These “non-classical” CD16+ monocytes are the primary producers of inflam-
matory cytokines IL-1β and TNF-α in inflammatory conditions40. Interestingly, recent data suggests TRIM21 
can be the factor that activates the proinflammatory properties of CD16+ monocytes41. In this context, certain 
monocyte subsets will be associated with increased TRIM21 expression and the proinflammatory condition in 
BD. Thus, TRIM21 expression in different monocyte subsets should be investigated in futures studies.
Figure 4. LPS-stimulated BD monocytes exhibited enhanced nuclear translocation of NF-kB. (a and b) 
Monocytes isolated from healthy controls and BD patients were stimulated with LPS (1 µg/ml) for 1 h. Cell 
lysates were evaluated by western blot for levels of phosphorylated p65. β-actin was used as the loading 
control. A representative result from four independent experiments is shown in (a). (c and d) THP-1 cells were 
transfected with scrambled RNA or TRIM21 siRNA (10 nM) for 24 h, and the transfected cells were stimulated 
with LPS (1 µg/ml) for 1 h. (e) THP-1 cells were transfected with scrambled RNA or TRIM21 siRNA (10 nM) 
for 24 h and were incubated with pNF-kB-Luc vector (500 ng) and pβ-galactosidase (500 ng) for 24 h. The 
transfected cells were stimulated with LPS (1 µg/ml) for 6 h. The results represent NF-kB luciferase activity, 
normalized for β-galactosidase. Data are represented as the mean ± SD. The cropped blots are displayed and 
full-length blots are shown in the Supplementary Information.
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TRIM proteins act as viral sensors and antiviral molecules1, 15. The role of viral infections, such as herpes 
simplex virus infection, in the BD pathogenesis has long been investigated42. Although the fundamental role of 
TRIM21 in herpesviruses, double-stranded DNA viruses, has not been reported; but the TRIM protein modulation 
of ubiquitination appears to be instrumental in the link between environmental factor and immunological disease.
In summary, our study revealed a previously unrecognized role of TRIM21 in regulating the secretion of 
proinflammatory cytokines from monocytes in BD. We found that TRIM21 was elevated and IRF-8 was 
down-regulated in monocytes from BD. Also, TRIM21 in monocytes stimulated NF-kB signaling in BD mono-
cyte. Finally, monocyte-derived proinflammatory cytokines, which promote Th1/Th17 inflammation, were reg-
ulated by TRIM21. Our results may have important implications for understanding the pathogenic role of the 
innate immune system in chronic inflammatory conditions.
Figure 5. BD monocytes promoted both Th1 and Th17 polarization after co-culture with effector T cells. (a and 
b) Primary monocytes from healthy controls or BD patients were co-cultured with allogeneic naïve CD4 + T 
cells in the presence of anti-CD3 (1 µg/ml) mAb and LPS (100 ng/ml) for 7 days. Cells were re-stimulated with 
PMA (50 ng/ml) and ionomycin (1 µg/ml) for 6 h in the presence of GolgiPlug for 4 h, and then expression of 
IL-17 and IFN-γ were determined by intracellular flow cytometry. (c) Production of IL-17A in monocyte/T-cell 
co-culture supernatant was quantified by ELISA. Data are represented as the mean ± SD. **P < 0.01. (d) Knock-
down TRIM21 in monocytes was co-cultured with allogeneic naïve CD4 + T cells in the presence of anti-CD3 
(1 µg/ml) mAb and LPS (100 ng/ml) for 48 h. Total RNA was extracted and analyzed by RT-PCR for mRNA 
expression of IL17A, IFNG, IL4, and IL13. Data are represented as the mean ± SD.
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